Cellulitis a review

JAMA - Journal of the American Medical Association

Volumn 316, Issue 3, 2016, Pages 325-337

  Raff, Adam B ^a   Kroshinsky, Daniela ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CEFALEXIN; CEFAZOLIN; CEFTAROLINE; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DICLOXACILLIN; ERYTHROMYCIN; IBUPROFEN; LINEZOLID; ORITAVANCIN; PENICILLIN G; PENICILLIN V POTASSIUM; PROCALCITONIN; TEDIZOLID; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BLOOD CULTURE; CELLULITIS; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DERMATITIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ECHOGRAPHY; ELEPHANTIASIS; ELEPHANTIASIS VERRUCOSA NOSTRA; ENDOCARDITIS; ERYTHEMA CHRONICUM MIGRANS; ERYTHROCYTE SEDIMENTATION RATE; FINE NEEDLE ASPIRATION BIOPSY; GLOMERULONEPHRITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHEDEMA; MEN WHO HAVE SEX WITH MEN; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY (TOPIC); NECROTIZING FASCIITIS; OSTEOMYELITIS; PATHOPHYSIOLOGY; PENICILLIN ALLERGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; STASIS DERMATITIS; STREPTOCOCCUS PYOGENES; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOXIC SHOCK SYNDROME; TREATMENT DURATION; ADULT; COMPLICATION; FEMALE; MALE; PRESCHOOL CHILD; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION;

ADULT; CELLULITIS; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS;

EID: 84979025649     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.8825     Document Type: Review

References (125)

1. Christensen KLY, Holman RC, Steiner C.A., Sejvar JJ, Stoll BJ, Schonberger LB. Infectious disease hospitalizations in the United States. Clin Infect Dis. 2009; 49(7):1025-1035. doi:10.1086/605562.
2. Hersh AL, Chambers HF, Maselli J.H., Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008; 168(14):1585-1591. doi:10.1001/archinte.168.14.1585.
3. Healthcare Cost and Utilization Project (HCUP). Nationwide Inpatient Sample (NIS) most frequent conditions in US hospitals, 2011. http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed November 2, 2014.
4. Goettsch WG, Bouwes Bavinck JN, Herings RMC. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol. 2006; 20(7):834-839. doi:10.1111/j.1468-3083.2006.01657.x.
5. Duvanel T, Auckenthaler R, Rohner P., Harms M, Saurat JH. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med. 1989; 149(2):293-296.
6. Chira S, Miller LG Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review. Epidemiol Infect. 2010; 138(3): 313-317. doi:10.1017/S0950268809990483.
7. Stevens DL, Bisno AL, Chambers H.F., et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59(2):e10-e52. doi:10.1093/cid/ciu296.
8. Gunderson CG, Martinello RA A systematic review of bacteremias in cellulitis and erysipelas. J Infect. 2012; 64(2):148-155. doi:10.1016/j.jinf.2011.11.004.
9. Khan T, Martin DH Streptococcus pneumoniae soft tissue infections in human immunodeficiency virus. Am J Med Sci. 2011; 342(3):235-238. doi:10.1097/MAJ.0b013e31820e811a.
10. Capdevila O, Grau I, Vadillo M., Cisnal M, Pallares R. Bacteremic pneumococcal cellulitis compared with bacteremic cellulitis caused by Staphylococcus aureus and Streptococcus pyogenes. Eur J Clin Microbiol Infect Dis. 2003; 22(6):337-341. doi:10.1007/s10096-003-0945-z.
11. Garcia-Lechuz J.M., Cuevas O, Castellares C., Perez-Fernandez C, Cercenado E, Bouza E; Spanish Pneumococcal Study Network. Streptococcus pneumoniae skin and soft tissue infections: characterization of causative strains and clinical illness. Eur J Clin Microbiol Infect Dis. 2007; 26(4): 247-253. doi:10.1007/s10096-007-0283-7.
12. Kim JE, Ko JY, Bae S.C., Ro YS. Tuberculous cellulitis as a manifestation of miliary tuberculosis in a patient with malignancy-associated dermatomyositis. J Am Acad Dermatol. 2011; 65(2): 450-452. doi:10.1016/j.jaad.2010.03.012.
13. Lee NH, Choi EH, Lee W.S., Ahn SK. Tuberculous cellulitis. Clin Exp Dermatol. 2000; 25(3):222-223.
14. Paterson DL, Gruttadauria S, Lauro A., Scott V, Marino IR. Spontaneous gram-negative cellulitis in a liver transplant recipient. Infection. 2001; 29(6): 345-347.
15. Ichiyama S, Hirai S, Minami T., et al. Campylobacter fetus subspecies fetus cellulitis associated with bacteremia in debilitated hosts. Clin Infect Dis. 1998; 27(2):252-255.
16. Bonner MJ, Meharg JG Jr. Primary cellulitis due to Serratia marcescens. JAMA. 1983; 250(17): 2348-2349.
17. Lev EI, Onn A, Levo O.Y., Giladi M. Hemophilus influenzae biotype III cellulitis in an adult. Infection. 1999; 27(1):42-43.
18. Crowe HM, Levitz RE Invasive Haemophilus influenzae disease in adults. Arch Intern Med. 1987; 147(2):241-244.
19. Burman WJ, Cohn DL, Reves R.R., Wilson ML. Multifocal cellulitis and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia. Clin Infect Dis. 1995; 20(3):564-570.
20. Chen YS, Liu YC, Yen M.Y., et al. Skin and soft-tissue manifestations of Shewanella putrefaciens infection. Clin Infect Dis. 1997; 25(2): 225-229.
21. Vuichard D, Conen A, Brenner M., Itin P, Flückiger U. Bullous cellulitis with Cryptococcus neoformans. Infection. 2011; 39(2):181-182. doi:10.1007/s15010-011-0082-z.
22. Anderson DJ, Schmidt C, Goodman J., Pomeroy C. Cryptococcal disease presenting as cellulitis. Clin Infect Dis. 1992; 14(3):666-672.
23. Neuville S, Dromer F, Morin O., Dupont B, Ronin O, Lortholary O; French Cryptococcosis Study Group. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis. 2003; 36(3): 337-347. doi:10.1086/345956.
24. Gauder JP. Cryptococcal cellulitis. JAMA. 1977; 237(7):672-673.
25. Dall Bello A.G., Severo CB, Schio S, Severo L.C., Severo LC. First reported case of cellulitis due to Cryptococcus gattii in lung transplantation recipient: a case report. Dermatol Online J. 2013; 19 (11):20395. http://escholarship.org/uc/item/99s03941 Accessed September 28, 2014.
26. Yang C-J, Wang C-S, Lu P-L, et al. Bullous cellulitis in cirrhotic patients - a rare but life-threatening infection caused by non-O1, non-O139 Vibrio cholerae bacteraemia. J Med Microbiol. 2011; 60(pt 6):861-862. doi:10.1099/jmm.0.024497-0.
27. Fernández J.M., Serrano M, De Arriba JJ, Sánchez MV, Escribano E., Ferreras P. Bacteremic cellulitis caused by non-01, non-0139 Vibrio cholerae: report of a case in a patient with hemochromatosis. Diagn Microbiol Infect Dis. 2000; 37(1):77-80.
28. Daniels NA. Vibrio vulnificus oysters: pearls and perils. Clin Infect Dis. 2011; 52(6):788-792. doi:10.1093/cid/ciq251.
29. Yoon TY, Jung SK, Chang SH Cellulitis due to Escherichia coli in three immunocompromised subjects. Br J Dermatol. 1998; 139(5):885-888.
30. Horowitz Y, Sperber AD, Almog Y. Gram-negative cellulitis complicating cirrhosis. Mayo Clin Proc. 2004; 79(2):247-250. doi:10.4065/79.2.247.
31. Yoshino Y, Abe M, Seo K., Koga I, Kitazawa T, Ota Y. Multifocal cellulitis due to disseminated Neisseria gonorrhoeae in a male patient. J Clin Med Res. 2014; 6(3):215-217. doi:10.14740/jocmr1732w.
32. Lau SM, Yu WL, Wang JH Cardiac cirrhosis with cellulitis caused by Burkholderia cepacia bacteremia. Clin Infect Dis. 1999; 29(2):447-448. doi:10.1086/520235.
33. Bhowmick T, Weinstein MP A deceptive case of cellulitis caused by a gram-negative pathogen. J Clin Microbiol. 2013; 51(4):1320-1323. doi:10.1128/JCM.02975-12.
34. Ruiz CC, Agraharkar M. Unusual marine pathogens causing cellulitis and bacteremia in hemodialysis patients: report of two cases and review of the literature. Hemodial Int. 2003; 7(4): 356-359. doi:10.1046/j.1492-7535.2003.00063.x.
35. Kennedy KJ, Roy J, Lamberth P. Invasive meningococcal disease presenting with cellulitis. Med J Aust. 2006; 184(8):421.
36. Finkelstein R, Oren I. Soft tissue infections caused by marine bacterial pathogens: epidemiology, diagnosis, and management. Curr Infect Dis Rep. 2011; 13(5):470-477. doi:10.1007/s11908-011-0199-3.
37. Abrahamian FM, Goldstein EJC. Microbiology of animal bite wound infections. Clin Microbiol Rev. 2011; 24(2):231-246. doi:10.1128/CMR.00041-10.
38. Talan DA, Citron DM, Abrahamian F.M., Moran GJ, Goldstein EJ; Emergency Medicine Animal Bite Infection Study Group. Bacteriologic analysis of infected dog and cat bites. N Engl J Med. 1999; 340 (2):85-92. doi:10.1056/NEJM199901143400202.
39. Griego RD, Rosen T, Orengo I.F., Wolf JE. Dog, cat, and human bites: a review. J Am Acad Dermatol. 1995; 33(6):1019-1029.
40. Jenkins TC, Sabel AL, Sarcone E.E., Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010; 51(8):895-903. doi:10.1086/656431.
41. Pallin DJ, Binder WD, Allen M.B., et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis. 2013; 56(12):1754-1762. doi:10.1093/cid/cit122.
42. Moran GJ, Krishnadasan A, Gorwitz R.J., et al; EMERGEncy ID Net Study Group. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med. 2006; 355(7):666-674. doi:10.1056/NEJMoa055356.
43. Miller LG, Perdreau-Remington F, Bayer A.S., et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S aureus infection: a prospective investigation. Clin Infect Dis. 2007; 44(4):471-482. doi:10.1086/511033.
44. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007; 357(4): 380-390. doi:10.1056/NEJMcp070747.
45. Dupuy A, Benchikhi H, Roujeau J.C., et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999; 318(7198):1591-1594.
46. Ginsberg MB. Cellulitis: analysis of 101 cases and review of the literature. South Med J. 1981; 74 (5):530-533.
47. Koutkia P, Mylonakis E, Boyce J. Cellulitis: evaluation of possible predisposing factors in hospitalized patients. Diagn Microbiol Infect Dis. 1999; 34(4):325-327.
48. Kulthanan K, Rongrungruang Y, Siriporn A., et al. Clinical and microbiologic findings in cellulitis in Thai patients. J Med Assoc Thai. 1999; 82(6):587-592.
49. CREST (Clinical Resource Efficiency Support Team). Guidelines on the Management of Cellulitis in Adults. CREST (Clinical Resource Efficiency Support Team); 2005:1-31.
50. Liu C, Bayer A, Cosgrove S.E., et al; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52(3):e18-e55. doi:10.1093/cid/ciq146.
51. McNamara DR, Tleyjeh IM, Berbari E.F., et al. Incidence of lower-extremity cellulitis: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2007; 82(7):817-821. doi:10.4065/82.7.817.
52. Karppelin M, Siljander T, Vuopio-Varkila J, et al. Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: a prospective case-control study. Clin Microbiol Infect. 2010; 16(6):729-734. doi:10.1111/j.1469-0691.2009.02906.x.
53. Björnsdóttir S, Gottfredsson M, Thórisdóttir AS, et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis. 2005; 41(10):1416-1422. doi:10.1086/497127.
54. Roujeau J-C, Sigurgeirsson B., Korting H-C, Kerl H, Paul C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology. 2004; 209(4): 301-307. doi:10.1159/000080853.
55. Eells SJ, Chira S, David C.G., Craft N., Miller LG. Non-suppurative cellulitis: risk factors and its association with Staphylococcus aureus colonization in an area of endemic community-associated methicillin-resistant S aureus infections. Epidemiol Infect. 2011; 139(4): 606-612. doi:10.1017/S0950268810001408.
56. Halpern J, Holder R, Langford NJ Ethnicity and other risk factors for acute lower limb cellulitis: a UK-based prospective case-control study. Br J Dermatol. 2008; 158(6):1288-1292. doi:10.1111/j.1365-2133.2008.08489.x.
57. Mokni M, Dupuy A, Denguezli M., et al. Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology. 2006; 212(2):108-112. doi:10.1159/000090649.
58. Bristow IR, Spruce MC Fungal foot infection, cellulitis and diabetes: a review. Diabet Med. 2009; 26(5):548-551. doi:10.1111/j.1464-5491.2009.02722.x.
59. Brewer VH, Hahn KA, Rohrbach B.W., Bell JL, Baddour LM. Risk factor analysis for breast cellulitis complicating breast conservation therapy. Clin Infect Dis. 2000; 31(3):654-659. doi:10.1086/314021.
60. McNamara DR, Tleyjeh IM, Berbari E.F., et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med. 2007; 167(7):709-715. doi:10.1001/archinte.167.7.709.
61. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Dtsch Dermatol Ges. 2004; 2(2):89-95.
62. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol. 2006; 155(5):947-950. doi:10.1111/j.1365-2133.2006.07419.x.
63. Morris A. Cellulitis and erysipelas. Clin Evid. 2006;(15):2207-2211.
64. Krasagakis K, Valachis A, Maniatakis P., Krüger-Krasagakis S, Samonis G, Tosca AD. Analysis of epidemiology, clinical features and management of erysipelas. Int J Dermatol. 2010; 49(9):1012-1017. doi:10.1111/j.1365-4632.2010.04464.x.
65. Lazzarini L, Conti E, Tositti G., de Lalla F. Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. J Infect. 2005; 51(5):383-389. doi:10.1016/j.jinf.2004.12.010.
66. Hook EW III, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med. 1986; 146(2):295-297.
67. Bates DW, Goldman L, Lee TH Contaminant blood cultures and resource utilization: the true consequences of false-positive results. JAMA. 1991; 265(3):365-369.
68. Lee PC, Turnidge J, McDonald PJ Fine-needle aspiration biopsy in diagnosis of soft tissue infections. J Clin Microbiol. 1985; 22(1):80-83.
69. Drinka P, Bonham P, Crnich CJ Swab culture of purulent skin infection to detect infection or colonization with antibiotic-resistant bacteria. J Am Med Dir Assoc. 2012; 13(1):75-79. doi:10.1016/j.jamda.2011.04.012.
70. Jenkins TC, Knepper BC, Sabel A.L., et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med. 2011; 171 (12):1072-1079. doi:10.1001/archinternmed.2011.29.
71. Assicot M, Gendrel D, Carsin H., Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993; 341(8844):515-518.
72. Sumer S, Erayman I, Aribas E. The role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and endotoxin in the early diagnosis and follow-up of local infections. http://www.nobelmedicus.com/en/Article.aspx?m=314. Published 2010. Accessed November 18, 2015.
73. Eder J, Hlavin G, Haushofer A., Trubert-Exinger D, Trautinger F. Correlation of serum procalcitonin with the severity of skin and skin structure infections: a pilot study. J Dtsch Dermatol Ges. 2012; 10(8):564-571. doi:10.1111/j.1610-0387.2011.07858.x.
74. Rast AC, Knobel D, Faessler L., et al. Use of procalcitonin, C-reactive protein and white blood cell count to distinguish between lower limb erysipelas and deep vein thrombosis in the emergency department: a prospective observational study. J Dermatol. 2015; 42(8):778-785. doi:10.1111/1346-8138.12922.
75. Wall DB, Klein SR, Black S, de Virgilio C. A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. J Am Coll Surg. 2000; 191(3):227-231.
76. Wong C-H, Khin L-W, Heng K-S, Tan K-C, Low C-O. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004; 32(7):1535-1541. doi:10.1097/01.CCM.0000129486.35458.7D.
77. Murphy G, Markeson D, Choa R., Armstrong A. Raised serum lactate: a marker of necrotizing fasciitis? J Plast Reconstr Aesthet Surg. 2013; 66(12): 1712-1716. doi:10.1016/j.bjps.2013.07.008.
78. Beltran J. MR imaging of soft-tissue infection. Magn Reson Imaging Clin N Am. 1995; 3(4):743-751.
79. Chaudhry AA, Baker KS, Gould E.S., Gupta R. Necrotizing fasciitis and its mimics: what radiologists need to know. AJR Am J Roentgenol. 2015; 204(1):128-139. doi:10.2214/AJR.14.12676.
80. Becker M, Zbären P, Hermans R., et al. Necrotizing fasciitis of the head and neck: role of CT in diagnosis and management. Radiology. 1997; 202 (2):471-476. doi:10.1148/radiology.202.2.9015076.
81. Wysoki MG, Santora TA, Shah R.M., Friedman AC. Necrotizing fasciitis: CT characteristics. Radiology. 1997; 203(3):859-863. doi:10.1148/radiology.203.3.9169717.
82. Zacharias N, Velmahos GC, Salama A, et al Diagnosis of necrotizing soft tissue infections by computed tomography. Arch Surg. 2010; 145(5): 452-455. doi:10.1001/archsurg.2010.50.
83. Alsaawi A, Alrajhi K, Alshehri A., Ababtain A, Alsolamy S. Ultrasonography for the diagnosis of patients with clinically suspected skin and soft tissue infections: a systematic review of the literature. Eur J Emerg Med. 2015. doi:10.1097/MEJ.0000000000000340.
84. Gunderson CG, Chang JJ Overuse of compression ultrasound for patients with lower extremity cellulitis. Thromb Res. 2014; 134(4):846-850. doi:10.1016/j.thromres.2014.08.002.
85. Gunderson CG, Chang JJ Risk of deep vein thrombosis in patients with cellulitis and erysipelas: a systematic review and meta-analysis. Thromb Res. 2013; 132(3):336-340. doi:10.1016/j.thromres.2013.07.02 1.
86. Falagas ME, Vergidis PI Narrative review: diseases that masquerade as infectious cellulitis. Ann Intern Med. 2005; 142(1):47-55.
87. Kroshinsky D, Grossman ME, Fox LP Approach to the patient with presumed cellulitis. Semin Cutan Med Surg. 2007; 26(3):168-178. doi:10.1016/j.sder.2007.09.002.
88. Levell NJ, Wingfield CG, Garioch JJ Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary care. Br J Dermatol. 2011; 164(6):1326-1328. doi:10.1111/j.1365-2133.2011.10275.x.
89. Strazzula L, Cotliar J, Fox L.P., et al. Inpatient dermatology consultation aids diagnosis of cellulitis among hospitalized patients: a multi-institutional analysis. J Am Acad Dermatol. 2015; 73(1):70-75. doi:10.1016/j.jaad.2014.11.012.
90. David CV, Chira S, Eells S.J., et al. Diagnostic accuracy in patients admitted to hospitals with cellulitis. Dermatol Online J. 2011; 17(3):1. http://escholarship.org/uc/item/9gn050rr. Accessed November 3, 2013.
91. Kilburn SA. Interventions for cellulitis and erysipelas. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004299.pub2/abstract. Accessed September 30, 2014.
92. Dong SL, Kelly KD, Oland R.C., Holroyd BR, Rowe BH. ED management of cellulitis: a review of five urban centers. Am J Emerg Med. 2001; 19(7): 535-540. doi:10.1053/ajem.2001.28330.
93. Singer M, Deutschman CS, Seymour C.W., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 (8):801-810.
94. Blumenthal KG, Shenoy ES, Varughese C.A., Hurwitz S., Hooper DC, Banerji A. Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. Ann Allergy Asthma Immunol. 2015; 115(4):294-300. e2.
95. Salkind AR, Cuddy PG, Foxworth JW The rational clinical examination. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA. 2001; 285 (19):2498-2505.
96. Lexicomp Online. Lexi-Comp Inc. http://online.lexi.com. Accessed May 16, 2016.
97. Johns Hopkins Guides. Cellulitis. http://www.hopkinsguides.com/hopkins/view/Johns-Hopkins-ABX-Guide/540106/all/Cellulitis. Accessed July 31, 2015.
98. Amin AN, Cerceo EA, Deitelzweig S.B., Pile JC, Rosenberg DJ, Sherman BM. Hospitalist perspective on the treatment of skin and soft tissue infections. Mayo Clin Proc. 2014; 89(10):1436-1451. doi:10.1016/j.mayocp.2014.04.018.
99. Madaras-Kelly K.J., Remington RE, Oliphant C.M., Sloan KL, Bearden DT. Efficacy of oral β-lactam versus non-β-lactam treatment of uncomplicated cellulitis. Am J Med. 2008; 121(5):419-425. doi:10.1016/j.amjmed.2008.01.028.
100. Peterson D, McLeod S, Woolfrey K., McRae A. Predictors of failure of empiric outpatient antibiotic therapy in emergency department patients with uncomplicated cellulitis. Acad Emerg Med. 2014; 21 (5):526-531. doi:10.1111/acem.12371.
101. Volz KA, Canham L, Kaplan E., Sanchez LD, Shapiro NI, Grossman SA. Identifying patients with cellulitis who are likely to require inpatient admission after a stay in an ED observation unit. Am J Emerg Med. 2013; 31(2):360-364. doi:10.1016/j.ajem.2012.09.005.
102. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20(6):864-874.
103. Waddington CS, Snelling TL, Carapetis JR Management of invasive group A streptococcal infections. J Infect. 2014; 69(suppl 1):S63-S69.
104. Kimberlin D, Brady M, Jackson M., Long S. American Academy of Pediatrics. Group A streptococcal infections. Red Book 2015. http://redbook.solutions.aap.org/chapter.aspx?sectionid=88187242&bookid=1484#91040571. Published 2015. Accessed May 6, 2016.
105. Yue J, Dong BR, Yang M, Chen X., Wu T, Liu GJ. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev. 2013; 7(7):CD008056. doi:10.1002/14651858.CD008056.pub2.
106. Ramsey TD, Lau TT, Ensom MH Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother. 2013; 47(4):543-560. doi:10.1345/aph.1R604.
107. Prokocimer P, De Anda C, Fang E, Mehra P., Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013; 309(6):559-569. doi:10.1001/jama.2013.241.
108. Pulia MS, Calderone MR, Meister J.R., Santistevan J., May L. Update on management of skin and soft tissue infections in the emergency department. Curr Infect Dis Rep. 2014; 16(9):418. doi:10.1007/s11908-014-0418-9.
109. Corey GR, Kabler H, Mehra P., et al; SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014; 370(23):2180-2190. doi:10.1056/NEJMoa1310422.
110. Moet GJ, Jones RN, Biedenbach D.J., Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 2007; 57(1):7-13. doi:10.1016/j.diagmicrobio.2006.05.009.
111. Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect. 2012; 65(2):128-134. doi:10.1016/j.jinf.2012.03.013.
112. Food and Drug Administration. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071185.pdf. Accessed May 31, 2015.
113. Hepburn MJ, Dooley DP, Skidmore P.J., Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004; 164(15):1669-1674. doi:10.1001/archinte.164.15.1669.
114. Dall L, Peterson S, Simmons T., Dall A. Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy. Cutis. 2005; 75(3):177-180.
115. Phoenix G, Das S, Joshi M. Diagnosis and management of cellulitis. BMJ. 2012; 345(2):e4955-e4955. doi:10.1136/bmj.e4955.
116. Dalal A. Interventions for the prevention of recurrent erysipelas and cellulitis. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009758/abstract. Accessed September 30, 2014.
117. Chlebicki MP, Oh CC Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment. Curr Infect Dis Rep. 2014; 16(9):422. doi:10.1007/s11908-014-0422-0.
118. Chartered Society of Physiotherapy. Physiotherapy works: lymphoedema. http://www.csp.org.uk/professional-union/practice/your-business/evidence-base/physiotherapy-works/lymphoedema. Accessed February 7, 2015.
119. Macmillan Cancer Support. Specialist lymphoedema services: an evidence review. http://www.macmillan.org.uk/Documents/AboutUs/Commissioners/LymphoedemaServicesAnEvidenceReview.pdf. Accessed February 7, 2015.
120. Elwell R. Developing a nurse-led integrated "red legs" service. Br J Community Nurs. 2014; 19(1): 12-19. doi:10.12968/bjcn.2014.19.1.12.
121. Bergkvist PI, Sjöbeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up. Scand J Infect Dis. 1998; 30(2):206-207.
122. Enzler MJ, Berbari E, Osmon DR Antimicrobial prophylaxis in adults. Mayo Clin Proc. 2011; 86(7): 686-701. doi:10.4065/mcp.2011.0012.
123. Oh CC, Ko HCH, Lee HY, Safdar N, Maki D.G., Chlebicki MP. Antibiotic prophylaxis for preventing recurrent cellulitis: a systematic review and meta-analysis. J Infect. 2014; 69(1):26-34. doi:10.1016/j.jinf.2014.02.011.
124. Thomas KS, Crook AM, Nunn A.J., et al; UK Dermatology Clinical Trials Network's PATCH I Trial Team. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013; 368(18):1695-1703. doi:10.1056/NEJMoa1206300.
125. Fritz SA, Camins BC, Eisenstein K.A., et al. Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with community-associated skin and soft-tissue infections: a randomized trial. Infect Control Hosp Epidemiol. 2011; 32(9):872-880. doi:10.1086/661285.